A practical approach to adjusting for attrition bias in HIV clinical trials with serial marker responses

被引:8
作者
Lepri, AC
Smith, GD
Mocroft, A
Sabin, CA
Morris, RW
Phillips, AN
机构
[1] Royal Free Hosp, Sch Med, Dept Primary Care & Populat Sci, HIV Res Unit, London NW3 2PF, England
[2] UCL, Sch Med, Dept Primary Care & Populat Sci, HIV Res Unit, London NW3 2PF, England
[3] Univ Bristol, Dept Social Med, Bristol, Avon, England
关键词
HIV clinical trials; drop-out; attrition; simulations;
D O I
10.1097/00002030-199810000-00007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To illustrate a simple approach to adjusting for bias due to drop-outs (i.e., attrition bias) when evaluating the effect of a certain therapy in HIV clinical trials using the mean change in plasma viral load. To evaluate its validity and to compare its performance with that of another simple method for handling dropouts: the last observation carried forward (LOCF) method. Design: Data from a notional treated group of 100 patients followed up to 52 weeks were generated. Attrition bias was introduced by mimicking selective patient dropout (i.e., more likely in patients doing badly). Methods: The difference between the true mean change in HIV RNA levels at 52 weeks and the observed mean change because of drop-outs was calculated (attrition bias). The reduction in bias obtained by using the proposed approach was then calculated and compared with that obtained by using the LOCF method. To assess the performance of the methods over the entire follow-up, the mean areas under the curves were considered. Results: Our method reduced the bias by a clinically relevant amount in a variety of different settings. In most of our simulations, bias was reduced by a larger amount than that obtainable from using the LOCF method. Conclusions: The current situation is that results from trials in HIV infection are invariably presented with no associated attempt to quantify the attrition bias present. Attrition-adjusted plots of mean change in HIV RNA should, we believe, be presented alongside usual plots as a form of sensitivity analysis. (C) 1998 Lippincott-Raven Publishers.
引用
收藏
页码:1155 / 1161
页数:7
相关论文
共 21 条
[1]   Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection [J].
Bartlett, JA ;
Benoit, SL ;
Johnson, VA ;
Quinn, JB ;
Sepulveda, GE ;
Ehmann, WC ;
Tsoukas, C ;
Fallon, MA ;
Self, PL ;
Rubin, M .
ANNALS OF INTERNAL MEDICINE, 1996, 125 (03) :161-+
[2]   Antiretroviral therapy for HIV infection in 1997 - Updated recommendations of the International AIDS Society USA panel [J].
Carpenter, CCJ ;
Fischl, MA ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (24) :1962-1969
[3]   Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine [J].
Collier, AC ;
Coombs, RW ;
Schoenfeld, DA ;
Bassett, RL ;
Timpone, J ;
Baruch, A ;
Jones, M ;
Facey, K ;
Whitacre, C ;
McAuliffe, VJ ;
Friedman, HM ;
Merigan, TC ;
Reichman, RC ;
Hooper, C ;
Corey, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (16) :1011-1017
[4]   A SHORT-TERM STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF RITONAVIR, AN INHIBITOR OF HIV-1 PROTEASE [J].
DANNER, SA ;
CARR, A ;
LEONARD, JM ;
LEHMAN, LM ;
GUDIOL, F ;
GONZALES, J ;
RAVENTOS, A ;
RUBIO, R ;
BOUZA, E ;
PINTADO, V ;
AGUADO, AG ;
DELOMAS, JG ;
DELGADO, R ;
BORLEFFS, JCC ;
HSU, A ;
VALDES, JM ;
BOUCHER, CAB ;
COOPER, DA ;
GIMENO, C ;
CLOTET, B ;
TOR, J ;
FERRER, E ;
MARTINEZ, PL ;
MORENO, S ;
ZANCADA, G ;
ALCAMI, J ;
NORIEGA, AR ;
PULIDO, F ;
GLASSMAN, HN .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (23) :1528-1533
[5]   Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection - A randomized, double-blind, placebo-controlled trial [J].
DAquila, RT ;
Hughes, MD ;
Johnson, VA ;
Fischl, MA ;
Sommadossi, JP ;
Liou, SH ;
Timpone, J ;
Myers, M ;
Basgoz, N ;
Niu, M ;
Hirsch, MS ;
Costanzo, L ;
Ruben, S ;
Berzins, B ;
Martinez, A ;
Fishman, I ;
Kazial, K ;
Cort, SN ;
Robinson, P ;
Hall, D ;
Macy, H ;
McLaren, C ;
Rooney, J ;
Warwick, J ;
CavailleColl, M ;
Valentine, F ;
Booth, D ;
Soeiro, R ;
Stein, D ;
Zingman, B ;
Schliosberg, J ;
Polsky, B ;
Sepkowitz, K ;
Sharpe, V ;
Giordano, M ;
Wanke, C ;
Gulick, R ;
Craven, D ;
Grodman, C ;
Fife, K ;
Black, J ;
Todd, K ;
Nixon, H ;
Sperber, K ;
Gerits, P ;
Mildvan, D ;
Nicholas, P ;
Murphy, RL ;
Kessler, H ;
Pulvirenti, J .
ANNALS OF INTERNAL MEDICINE, 1996, 124 (12) :1019-1030
[6]  
DeGruttola V, 1998, AIDS, V12 Suppl A, pS149
[7]   TREATMENT WITH LAMIVUDINE, ZIDOVUDINE, OR BOTH IN HIV-POSITIVE PATIENTS WITH 200 TO 500 CD4+ CELLS PER CUBIC MILLIMETER [J].
ERON, JJ ;
BENOIT, SL ;
JEMSEK, J ;
MACARTHUR, RD ;
SANTANA, J ;
QUINN, JB ;
KURITZKES, DR ;
FALLON, MA ;
RUBIN, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) :1662-1669
[8]   COMBINATION AND MONOTHERAPY WITH ZIDOVUDINE AND ZALCITABINE IN PATIENTS WITH ADVANCED HIV DISEASE [J].
FISCHL, MA ;
STANLEY, K ;
COLLIER, AC ;
ARDUINO, JM ;
STEIN, DS ;
FEINBERG, JE ;
ALLAN, JD ;
GOLDSMITH, JC ;
POWDERLY, WG ;
RAINES, CP ;
MAYJO, KJ ;
KERULY, JC ;
CRAVEN, D ;
HIRSHORN, L ;
HIRSCH, MS ;
JAYAWEERA, DT ;
YOUNG, SW ;
PATRONEREESE, J ;
BRETTLER, D ;
SPERBER, K ;
GERITS, P ;
SEREMETIS, S ;
GILL, JC ;
GELB, LD ;
MCGUIRE, ML ;
STIFFLER, T ;
LEDERMAN, MM ;
CAREY, JT ;
WALLACE, M ;
MACARTHUR, RD ;
BERGE, P ;
MILDVAN, D ;
COREY, L ;
COOMBS, RW ;
CUMMINGS, DK ;
SCHOOLEY, RT ;
RAY, MG ;
WAITE, V ;
KURITZKES, DR ;
FUHRER, J ;
TENZLER, RJ ;
DONLON, W ;
VANDERHORST, CM ;
TROIANI, L ;
HORTON, J ;
LANE, TW ;
MURPHY, RR ;
PHAIR, JP ;
KESSLER, HA ;
BENSON, CA .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (01) :24-32
[9]  
GILLINGS D, 1991, DRUG INF J, V25, P411, DOI DOI 10.1177/009286159102500311
[10]   A NEW APPROACH TO THE ANALYSIS OF CLINICAL DRUG TRIALS WITH WITHDRAWALS [J].
GOULD, AL .
BIOMETRICS, 1980, 36 (04) :721-727